Welcome to our dedicated page for TAKEDA PHARMACEUTICAL CO SEC filings (Ticker: TAK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TAKEDA PHARMACEUTICAL CO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TAKEDA PHARMACEUTICAL CO's regulatory disclosures and financial reporting.
Takeda Pharmaceutical Company Limited has a shareholder planning to sell American Depositary Shares (ADSs). The planned sale covers up to 4,319 ADSs of Takeda, to be executed through Interactive Brokers LLC on or after July 13, 2026 on the NYSE. The securities to be sold were received as Restricted Stock Unit awards that vested on July 1, 2026, with a separate entry showing 13,988 ADSs acquired on that date as compensation.
Takeda Pharmaceutical Company Limited submitted a notice for the proposed sale of American Depositary Shares (ADSs) under Rule 144. The notice covers up to 7,889 ADSs, to be sold through Interactive Brokers LLC on the NYSE on or after July 13, 2026, with an indicated aggregate market value of $132,148.97. It also lists activity in the prior three months, including 25,586 ADSs related to Restricted Stock Unit Awards – Vested dated July 1, 2026, categorized as compensation.
Takeda Pharmaceutical Company Limited reports a planned sale of 15,188 American Depositary Shares (ADSs) of its stock through Interactive Brokers LLC on the NYSE on July 13, 2026, with an aggregate market value of $254,398.88. The ADSs relate to previously issued equity compensation, and 143,310,556 shares of the issuer’s securities are reported as outstanding. During the prior three months, 38,982 ADSs tied to vested Restricted Stock Unit awards were sold on July 1, 2026 for compensation purposes.
Takeda Pharmaceutical Company Limited has filed a notice for the potential sale of American Depositary Shares (ADSs) under Rule 144. The planned transaction involves 50,582 ADSs, which were acquired on July 1, 2026 through vested Restricted Stock Unit Awards. The ADSs are listed on the NYSE and the broker named for the transaction is Interactive Brokers LLC. The filing characterizes the acquisition as compensation-related and indicates that the securities to be sold are ADSs of Takeda.
A holder of Takeda Pharmaceutical Company Limited American Depositary Shares (ADSs) has filed to sell up to 179,239 ADSs through Interactive Brokers LLC on the NYSE, with a stated aggregate market value of $3,002,257.72. The transaction is referenced with a date of July 13, 2026.
The ADSs relate to Restricted Stock Unit awards that vested on July 1, 2026, categorized as compensation, with 358,730 ADSs shown in connection with those vested awards. No securities sold during the past three months are listed.
A holder of Takeda Pharmaceutical Company Limited American Depositary Shares plans to sell up to 54,210 ADSs on the NYSE, through Interactive Brokers LLC, with an indicated aggregate market value of $908,019.02 as of 07/13/2026.
The securities relate to Restricted Stock Unit awards that vested on 07/01/2026, when 114,144 ADSs were acquired as compensation.
Takeda Pharmaceutical Company Limited filed a notice relating to American Depositary Shares (ADSs) traded on the NYSE. The ADSs were acquired through Restricted Stock Unit Awards that vested on 07/01/2026 as part of compensation. Interactive Brokers LLC is listed as the broker. The filing also reports 190,406 ADSs sold on 07/01/2026 in connection with compensation during the past three months.
Takeda Pharmaceutical Company Limited furnishes a detailed Corporate Governance Report describing how it manages its global biopharmaceutical business. The company states it complies with all principles of Japan’s Corporate Governance Code, with an 11-member Board of Directors that includes eight Independent External Directors and is chaired by an independent director. Takeda emphasizes strong oversight via an Audit and Supervisory Committee made up entirely of Independent External Directors, plus nomination and compensation committees composed solely of externals.
The report highlights shareholder structure and engagement. Foreign shareholders hold 30% or more of shares as of the end of March 2026, and the two largest trust bank shareholders each own more than 5%. Takeda describes extensive investor-relations activities, early and bilingual AGM materials, electronic voting, and regular dialogue with institutional and retail investors. It confirms no anti-takeover measures and no controlling shareholder.
Takeda stresses sustainability and stakeholder focus, including climate, nature, and product sustainability programs, and disclosures aligned with TCFD and TNFD. It describes diversity and human capital initiatives: in Japan, women account for 22.5% of managers and 4.1% of managers are non-Japanese as of March 31, 2026, while globally women hold 43% of management roles. The company outlines leadership development, digital upskilling, flexible leave and housing benefits, and a 2.92% employment rate for people with disabilities in Japan.
Takeda Pharmaceutical Company Limited completed the issuance of new shares and disposal of treasury shares on July 8, 2026 under its long-term incentive plan for group employees outside Japan. After a partial forfeiture of rights by some planned allottees, the company issued and disposed of 16,877,109 ordinary shares at 5,050 yen per share, comprising 10,780,950 new shares and 6,096,159 treasury shares, for a total value of 85,229,400,450 yen. Takeda states that the resulting changes from the previously planned figures are expected to have an immaterial impact on full-year financial results for the fiscal year ending March 31, 2027.
Takeda Pharmaceutical director Steven Gillis reported compensation-related equity awards and a tax settlement. On July 1, 2026, he received 3,800 Ordinary Shares as a grant and 1,319 "Tax Obligation Awards," each economically equivalent to one Ordinary Share and intended to be cash-settled at vesting mainly to cover tax obligations.
The filing notes an earlier RSU vesting where 3,100 Ordinary Shares were converted into 6,200 American Depositary Shares. On July 10, 2026, 1,152 Tax Obligation Awards were disposed of to the issuer, with the associated Ordinary Shares sold at a weighted average of JPY 4,931.2 per share; remaining proceeds from those sales are to be delivered to Gillis. Following these events, he holds 22,057 American Depositary Shares directly, and the RSU and Tax Obligation Awards are scheduled to vest on June 1, 2029.